Smithkline Beecham Corporation

Bicycletx Limited

Convergence Pharmaceuticals Limited

Glaxo Group Limited

University College Cardiff Consultants Limited

Skidmore, John

Modi, Sandeep

Beswick, Paul

Pegg, Neil

Swarbrick, Martin

Paul John Beswick

Gemma Elizabeth Mudd

Katerine Van Rietschoten

Robert James Gleave

Sadie Vile

Peter U Park

Vipulkumar Kantibhai Patel

Liuhong Chen

Michael Skynner

Michael Rigby

Gabriela Ivanova-Berndt

Alan Naylor

Ian B Campbell

Andrew Peter Cridland

Jag Paul Heer

Savvas Kleanthous

Neville Hubert Nicholson

Simon Ward

Lee William Page

Lewis Pennicott

Tristan Reuillon

Alister Campbell

Daniel Paul Teufel

Kevin McDonnell

Simon Edward Ward

Silvia Pavan

Robert John Young

David Witty

Michael Lawrence Sierra

Neil Mathews

Irina Chuckowree

Shuji Hachisu

Carolina Villalonga-Barber

Roderick Alan Porter

Alexander W Oxford

Ian H Coates

Peter C North

John David Harling

David Kenneth Dean

Neil Anthony Pegg

Nigel Paul King

Millard Hurst Lambert, Iii

Romain Luc Marie Gosmini

Daryl Simon Walter

Martin Edward Swarbrick

Charanjit Bountra

Juliet Kay Simpson

John Skidmore

Nicholas Keen

Stephen Blakemore

Andrew Peter Moses

Sandeep Modi

Richard Bell

Nicolas Bertheleme

Richard Martin Grimes

Christopher Charles Frederick Hamlett

Christopher Charles Hamlett

Nicholas Bertheleme

Nigel Grahame Ramsden

Neil Matthews

Tara Gelb

Simon E Ward

Neil Pegg

Peter Park

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Bicyclic peptide ligands specific for Nectin-4

The invention provides compounds of the formula (I): (I) wherein A, A, R, R, B, B, X, X, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

Compounds that modulates AMPA receptor function

Bicyclic peptide ligands specific for nectin-4

The present invention provides compounds, compositions thereof, and methods of using the same.

Bicyclic peptide ligands and uses thereof

The invention provides compounds of the formula (I): (I) wherein A, A, R, R, B, B, X, X, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia. 

The invention provides compounds of the formula (I): wherein Rand Rare defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia. 

AMPA receptor potentiators

The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial. Formula (I) wherein A is: (II) or (III)  

Tetrazole compounds as calcium channel blockers

The present invention relates to novel tetrazole compounds of Formula (I) wherein A is (II) or (III); to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial. wherein A is 

The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial.

3-pyridylcarbonyl-piperazinylsulfonyl derivatives

The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial.

Piperazine derivatives used as CAV2.2 calcium channel modulators

Growing community of inventors

Harlow, United Kingdom

Paul John Beswick